{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:14:00Z","timestamp":1762503240900,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ctro.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T04:02:25Z","timestamp":1614052945000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience"],"prefix":"10.1016","volume":"28","author":[{"given":"Krishan R.","family":"Jethwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney N.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harigopal","family":"Sandhyavenu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Gonuguntla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Routman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison E.","family":"Garda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joleen M.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Neben-Wittich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth W.","family":"Merrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Hallemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Haddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2021.02.002_b0005","doi-asserted-by":"crossref","unstructured":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348(9034):1049\u201354.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"issue":"16","key":"10.1016\/j.ctro.2021.02.002_b0010","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ctro.2021.02.002_b0015","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctro.2021.02.002_b0020","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ctro.2021.02.002_b0025","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2021.02.002_b0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2021.02.002_b0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0045","first-page":"1","article-title":"Quality of life after radiotherapy for rectal and anal cancer","volume":"16","author":"Neibart","year":"2020","journal-title":"Curr Colorectal Cancer Rep"},{"issue":"2","key":"10.1016\/j.ctro.2021.02.002_b0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2019.10.016","article-title":"Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma","volume":"106","author":"Shakir","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2018.05.044","article-title":"Intensity modulated radiation therapy versus conventional radiation for anal cancer in the veterans affairs system","volume":"102","author":"Bryant","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/COC.0000000000000009","article-title":"Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study","volume":"39","author":"Call","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2021.02.002_b0065","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ijrobp.2018.04.033","article-title":"Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort","volume":"101","author":"Jones","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2021.02.002_b0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13014-018-1124-9","article-title":"Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study","volume":"13","author":"Franco","year":"2018","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2021.02.002_b0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ajco.12768","article-title":"Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer","volume":"14","author":"Arcadipane","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2021.02.002_b0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/COC.0b013e31827e52a3","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity","volume":"37","author":"Mitchell","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.02.002_b0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13014-015-0477-6","article-title":"French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients","volume":"10","author":"Vendrely","year":"2015","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2021.02.002_b0095","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijrobp.2014.06.061","article-title":"Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer","volume":"90","author":"Han","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2021.02.002_b0100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.radonc.2015.08.008","article-title":"Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer","volume":"117","author":"Joseph","year":"2015","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2021.02.002_b0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/07357907.2015.1028586","article-title":"Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series","volume":"33","author":"Franco","year":"2015","journal-title":"Cancer Invest"},{"issue":"29","key":"10.1016\/j.ctro.2021.02.002_b0110","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2007.12.0170","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience","volume":"25","author":"Salama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2021.02.002_b0115","doi-asserted-by":"crossref","first-page":"e0194234","DOI":"10.1371\/journal.pone.0194234","article-title":"Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy","volume":"13","author":"Foster","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ctro.2021.02.002_b0120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.ijrobp.2009.09.046","article-title":"Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis","volume":"78","author":"Pepek","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.ctro.2021.02.002_b0130","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.clon.2015.08.006","article-title":"Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3\u00a0year outcomes at two Sydney institutions","volume":"27","author":"Yates","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctro.2021.02.002_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1748-717X-7-45","article-title":"IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center","volume":"7","author":"Vieillot","year":"2012","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.prro.2012.02.005","article-title":"Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: a retrospective review from a large academic center","volume":"3","author":"Call","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2021.02.002_b0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1748-717X-9-199","article-title":"Clinical experience of SIB-IMRT in anal cancer and selective literature review","volume":"9","author":"Janssen","year":"2014","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2021.02.002_b0150","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2021.02.002_b0155","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2021.02.002_b0160","unstructured":"ECOG-ACRIN trial 2165: nivolumab after combined modality therapy in treating patients with high risk stage II-IIIB anal cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03233711."},{"key":"10.1016\/j.ctro.2021.02.002_b0165","unstructured":"ECOG-ACRIN trial 2182: lower-dose chemoradiation in treating patients with early-stage anal cancer, the DECREASE study."},{"key":"10.1016\/j.ctro.2021.02.002_b0170","unstructured":"PLATO \u2013 personalising anal cancer radiotherapy dose. Available from: http:\/\/www.isrctn.com\/ISRCTN88455282."},{"key":"10.1016\/j.ctro.2021.02.002_b0175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejca.2020.09.039","article-title":"Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer","volume":"141","author":"Lerman","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctro.2021.02.002_b0180","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2011.06.010","article-title":"Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer","volume":"101","author":"Alsadius","year":"2011","journal-title":"Radiother Oncol"},{"issue":"17","key":"10.1016\/j.ctro.2021.02.002_b0185","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2002.10.128","article-title":"Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer","volume":"20","author":"Eifel","year":"2002","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ctro.2021.02.002_b0190","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87\u201304 and 98\u201311","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.02.002_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.06.012","article-title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus. Results of a post-hoc analysis from the randomized phase III ACT II trial","author":"Glynne-Jones","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2021.02.002_b0200","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ijrobp.2017.02.218","article-title":"Final report of a prospective randomized trial to evaluate the dose-response relationship for postoperative radiation therapy and pathologic risk groups in patients with head and neck cancer","volume":"98","author":"Rosenthal","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2021.02.002_b0205","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2013.07.035","article-title":"Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98\u201311 phase 3 trial","volume":"87","author":"Gunderson","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2021.02.002_b0210","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/j.ijrobp.2011.02.042","article-title":"Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292)","volume":"81","author":"Chakravarthy","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijrobp.2007.12.027","article-title":"Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92\u201308","volume":"72","author":"Konski","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.ctro.2021.02.002_b0220","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctro.2021.02.002_b0225","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1200\/JCO.2007.15.2348","article-title":"HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy","volume":"26","author":"Oehler-J\u00e4nne","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2021.02.002_b0230","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.radonc.2013.08.002","article-title":"p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy","volume":"109","author":"Gilbert","year":"2013","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630821000161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630821000161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:09:27Z","timestamp":1762502967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630821000161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":46,"alternative-id":["S2405630821000161"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2021.02.002","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}